Programmed cell death protein 1 and programmed cell death ligand 1 (PD-1/PD-L1) inhibitors have been developed as postoperative chemotherapy for various cancer types, and numerous clinical trials have shown that they have high therapeutic efficacy [4]. Here, PDCD1 is linked to cancer.